Physician profile
William E Kalafatic
NPI 1992960538
$7,268.47
in general payments reported to CMS, 2019-2025
28 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $276 · 2021: $2,099 · 2022: $1,459 · 2023: $1,010 · 2024: $553 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Travel and Lodging: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.70 |
| Travel and Lodging | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,145.57 | 2019-2024 | |
| Novo Nordisk INC | $1,006.94 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $749.69 | 2021-2024 | Corevalve Evolut R, Onyx Frontier, Euphora |
| Astrazeneca Pharmaceuticals LP | $645.76 | 2019-2024 | Farxiga, Lynparza |
| Janssen Pharmaceuticals, INC | $481.30 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.59 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $311.10 | 2022 | |
| Abbott Laboratories | $306.40 | 2019-2021 | |
| Esperion Therapeutics, INC. | $299.92 | 2021-2022 | |
| Heartflow, INC. | $293.65 | 2023-2025 | Ffrct |
| Merck Sharp & Dohme LLC | $271.43 | 2021-2025 | Verquvo |
| Pfizer INC. | $240.12 | 2019-2025 | |
| Biotronik INC. | $160.45 | 2021 | |
| Lilly USA, LLC | $152.91 | 2019-2023 | Mounjaro |
| Actelion Pharmaceuticals US, INC. | $129.46 | 2023-2024 | Opsumit, Uptravi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $103.73 | 2019-2025 | Eliquis |
| Boston Scientific Corporation | $97.20 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.48 | 2019-2021 | |
| Edwards Lifesciences Corporation | $65.06 | 2019-2020 | |
| Medtronic Vascular, INC. | $35.21 | 2020 | |
| Scpharmaceuticals INC. | $34.66 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $31.25 | 2021 | |
| Idorsia Pharmaceuticals US INC | $25.08 | 2025 | Tryvio |
| Regeneron Healthcare Solutions, INC. | $24.19 | 2019 | |
| Amarin Pharma, INC. | $21.77 | 2019 | |
| Medicomp INC | $18.67 | 2025 | Telepatch Cardiac Monitor |
| Bridgebio Pharma, INC. | $16.88 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kalafatic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.